| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5657292 | Clinical Gastroenterology and Hepatology | 2017 | 42 Pages |
Abstract
In a retrospective analysis of patients with IBD receiving proactive vs reactive monitoring of serum concentration of infliximab, proactive monitoring was associated with better clinical outcomes, including greater drug durability, less need for IBD-related surgery or hospitalization, and lower risk of antibodies to infliximab or serious infusion reactions.
Keywords
TNFHMSATDMSAEATIIQRROCSIRIBDantibodies to infliximabImmunogenicityCrohn’s diseaseInflammatory bowel diseaseEnzyme-linked immunosorbent assayELISATrough concentrationSerious adverse eventconfidence intervaltumor necrosis factorinterquartile rangehazard ratiotherapeutic drug monitoringUlcerative colitisreceiver operating characteristic
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Konstantinos Papamichael, Karen A. Chachu, Ravy K. Vajravelu, Byron P. Vaughn, Josephine Ni, Mark T. Osterman, Adam S. Cheifetz,